PRICING STRATEGIES AND TRENDS OF FDA APPROVED NSCLC THERAPIES FROM 2018 TO 2023

被引：0
|
作者：
Cheng, S. Y. [1 ]
Ambegaonkar, A. J. [2 ]
机构：
[1] APPERTURE LLC, Baltimore, MD USA
[2] APPERTURE LLC, Marlboro, NJ USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE297
引用
收藏
页码：S112 / S112
页数：1
相关论文
共 48 条
  • [1] Trends in FDA-Approved Cancer Therapies
    Hilas, Olga
    US PHARMACIST, 2023, 48 (10) : 14 - 14
  • [2] Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs
    Tompa, Dharma Rao
    Immanuel, Aruldoss
    Srikanth, Srimari
    Kadhirvel, Saraboji
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2021, 172 : 524 - 541
  • [3] Pharmacological aspects of FDA-approved novel drug therapies against cancer in 2023: a comprehensive review
    Sangwan, Kavita
    Goyal, Parveen Kumar
    Sharma, Vipasha
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2025,
  • [4] Fluorine in anti-HIV drugs approved by FDA from 1981 to 2023
    Han, Sheng
    Lu, Yiming
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 258
  • [5] The US FDA approved cardiovascular drugs from 2011 to 2023: A medicinal chemistry perspective
    Jiang, Yunhan
    Liu, Pingxian
    Qiu, Zhiqiang
    Zhou, Meng
    Cheng, Mengdi
    Yang, Tao
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 275
  • [6] TRENDS IN TRACHEOSTOMY: A COMPARATIVE ANALYSIS FROM 2018 TO 2023
    Dixit, Keshav
    Ishisaka, Yoshiko
    De Frias, Jorge Sinclair
    Chen, Shasha X.
    Miyakawa, Lina
    Rothman, Adam
    CHEST, 2024, 166 (04) : 5180A - 5181A
  • [7] Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies
    Subbiah, Vivek
    Hess, Kenneth R.
    Khawaja, Muhammad Rizwan
    Wagner, Michael J.
    Tang, Chad
    Naing, Aung
    Fu, Siqing
    Janku, Filip
    Piha-Paul, Sarina
    Tsimberidou, Apostolia M.
    Herzog, Cynthia E.
    Ludwig, Joseph A.
    Patel, Shreyaskumar
    Ravi, Vinod
    Benjamin, Robert S.
    Meric-Bernstam, Funda
    Hong, David S.
    SCIENTIFIC REPORTS, 2016, 6
  • [8] Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies
    Vivek Subbiah
    Kenneth R. Hess
    Muhammad Rizwan Khawaja
    Michael J. Wagner
    Chad Tang
    Aung Naing
    Siqing Fu
    Filip Janku
    Sarina Piha-Paul
    Apostolia M. Tsimberidou
    Cynthia E. Herzog
    Joseph A. Ludwig
    Shreyaskumar Patel
    Vinod Ravi
    Robert S. Benjamin
    Funda Meric-Bernstam
    David S. Hong
    Scientific Reports, 6
  • [9] Kinase Inhibitors FDA Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities
    Latham, Bethany D.
    Geffert, Raeanne M.
    Jackson, Klarissa D.
    DRUG METABOLISM AND DISPOSITION, 2024, 52 (06) : 479 - 492
  • [10] Value of Molecular Targets and Genome-Targeted Therapies FDA-Approved for Metastatic Breast Cancer, 2006-2023
    Tibau, Ariadna
    Hwang, Thomas J.
    Valiente, Consolacion Molto
    Avorn, Jerry
    Kesselheim, Aaron
    CANCER RESEARCH, 2024, 84 (09)
12345